Biogen bonus as generic Tecfidera approvals are pulled in EU

The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua

Whistleblower gets $250m as Biogen settles US kickbacks case

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

NICE backs Biogen's Vumerity for multiple sclerosis

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a patent challenge – but will the boost mean much when the company still fac

Biogen claims victory in patent dispute with Mylan over MS d...

Biogen bags FDA okay for Tecfidera follow-up Vumerity